Published in

Nature Research, Nature Communications, 1(7), 2016

DOI: 10.1038/ncomms12595

Links

Tools

Export citation

Search in Google Scholar

Stratification and therapeutic potential of PML in metastatic breast cancer

Journal article published in 2016 by Natalia Martín Martín, Marco Piva, Maria D. M. Vivanco, Jelena Urosevic, Paula Aldaz, James D. Sutherland ORCID, Sonia Fernández Ruiz, Leire Arreal, Ana R. Cortazar, Verónica Torrano, Stephane Garcia, Amaia Zabala Letona, Evarist Planet, Iratxe Macías, Patricia Zúñiga García ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractPatient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target in aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast tumours is accompanied by the elevated PML expression and enhanced sensitivity to its inhibition. Interestingly, we find that STAT3 is responsible, at least in part, for the transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in combination with PML-based stratification.